Following the announcement in January 2007 of its intent, Siemens Medical Solutions has announced that it has received antitrust approval and completed its acquisition of Gesellschaft fur Systemforschung und Dienstleistungen im Gesundheitswesen mbH (GSD), headquartered in Berlin. The new entity, Siemens Medical Solutions GSD GmbH, will remain a separate legal entity, operating as a wholly owned subsidiary of Siemens Medical Solutions as part of the Health Services (HS) Division. With this acquisition Siemens strengthens its position in the European healthcare IT market.

With more than 300 customers in 14 countries, GSD is a leading health information systems (HIS) company. With the addition of GSD's i.s.h.med and i.c.m.health product lines, the move enhances Siemens' global healthcare IT portfolio and infuses additional industry expertise into its product and service offerings for the European market. GSD generated a revenue of 23.6 million EUR and employed 167 people in fiscal year 2006 (ended December 31). "We are pleased to officially welcome the talent and resources of GSD into our trendsetting healthcare IT portfolio," said Erich R. Reinhardt, member of the Managing Board of Siemens AG, and President and CEO of Siemens Medical Solutions. "As with our continued investments in our Soarian healthcare process management solution, which is distinguished by its unique architecture and workflow engine, and with the internationally successful health information system, i.s.h.med, we see tremendous potential for best practice sharing and optimized service and support for our customers through this investment in GSD."
The combined product portfolio is unique in its regional and functional market coverage, enabling Siemens to tailor its solution offerings for customers at various levels of IT sophistication and maturity.


"We remain steadfast in our commitment to improving the quality and reducing the cost of healthcare through IT, which has become an essential component of our global strategy as we move toward more personalized medicine," Reinhardt added. "Today, we are taking an important step in improving our market position in Germany and expanding our presence in Europe. Additionally, we have high expectations that the combined business expertise and industry knowledge of the HS and GSD teams will ensure that our product and service innovation continues, our customers are well-positioned to achieve their desired outcomes, and that we are successful in all markets we serve."

More Industry Headlines